ClinicalTrials.gg
RecruitingNCT07161245RELIEFUpdated Sep 8, 2025

RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis

An interventional study of Multimodal prehabilitation and standard of care in Primary Biliary Cholangitis (PBC), sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2025, registered Jun 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Liver Cirrhosis, Biliary with a site in Spain — 7 open to participants now, 12 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Spain.

Planned enrollment
20th of 26
64 · median 129
Started
2025
with 2 others
No phase
Only one
of the 32
Primary completion
2026-09
later than 3 of 11 live
Registered
29th of 32
by date

Among the 32 studies in Liver Cirrhosis, Biliary with a site in Spain, this one is the 20th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2025, is the only one with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 29th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

7 of the 32 studies in Liver Cirrhosis, Biliary with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Liver Cirrhosis, Biliary with a site in Spain, or all of them as a file.
02

Study summary

The implementation of a non-pharmacological multimodal intervention program-including physical exercise, nutritional counseling, and psychological support-is expected to improve fatigue in patients with primary biliary cholangitis. Consequently, this improvement is anticipated to enhance quality of life and cognitive symptoms, while also positively impacting emotional, social, and occupational aspects.

From a pathophysiological perspective, it is hypothesized that chronic cholestasis and/or immune system activation, with the release of pro-inflammatory cytokines, leads to both central and peripheral alterations causing fatigue.

At the central level, systemic inflammation may induce neuronal senescence in the basal ganglia, resulting in altered functional connectivity networks dependent on these regions and/or structural and connectivity changes in areas involved in interoception, such as the insula and anterior cingulate cortex.

At the peripheral level, the hypothesis is that chronic inflammation mediated by anti-mitochondrial antibodies causes mitochondrial metabolic dysfunction in muscle cells, which would be reflected in changes observed in the gene expression analysis of these cells.

Improvement in fatigue following the multimodal intervention program is expected to be associated with normalization of the immunological profile, enhanced functional brain connectivity, and improved mitochondrial metabolism in muscle.

Read the detailed description

Primary biliary cholangitis (PBC) is a rare autoimmune disease that damages the small bile ducts and primarily affects women. Although it is a liver disease, its most common symptom is fatigue, affecting up to 60% of patients. Fatigue is a debilitating symptom, described by patients as "a brain fog" that causes concentration problems and memory loss, along with "a lack of energy" that leads to poor exercise tolerance and early exhaustion. This significantly impacts quality of life, negatively affecting family, social, and work-related activities. To the frustration of both patients and healthcare providers, fatigue is not correlated with the severity of liver disease, and there is currently no effective treatment.

Ursodeoxycholic acid (UDCA), the first-line treatment for PBC, has been shown to improve disease survival, but it does not appear to have an effect on fatigue, as demonstrated by a meta-analysis. Other treatments, such as bezafibrate, have also failed to show improvement in fatigue. Several clinical trials have tested treatments targeting different pathophysiological mechanisms, including selective serotonin reuptake inhibitors (SSRIs), stimulants like modafinil, and immunomodulatory therapies such as rituximab, all with negative results.

Currently, new drugs have been approved as second-line treatments for PBC, such as elafibranor and seladelpar. The latter may have some impact on fatigue; however, this was not the primary objective of the study, and the mechanisms associated with this improvement remain unclear.

One of the main reasons why no treatment exists is the lack of understanding of the underlying mechanisms. Fatigue is a complex and likely multifactorial symptom. It has been hypothesized that chronic immune system activation, leading to excessive production of inflammatory substances, could be a trigger. Additionally, it remains unknown whether alterations in bile acid composition, which are molecules with potent biological effects on multiple organs, could worsen fatigue. Furthermore, this chronic inflammation may induce changes in both the brain and muscles, contributing to the development of fatigue.

It has been demonstrated that physical exercise reduces systemic inflammation by lowering inflammatory substances and can also improve abnormalities in muscle energy production. Studies conducted in patients with other diseases associated with fatigue, such as multiple sclerosis, have shown that exercise programs can be beneficial for fatigue management.

At present, experience with physical training programs for PBC patients with fatigue is very limited. The results of a study conducted in the United Kingdom and another in Canada suggest that a home-based exercise program may improve fatigue. However, both studies have certain limitations, as the follow-up was remote, there was no supervision to ensure proper execution of the exercises or that they were performed at the prescribed intensity. Additionally, the effective exercise duration was only about 15 minutes, which, along with its moderate intensity, is unlikely to induce specific adaptations in mitochondrial biogenesis and efficiency. On the other hand, while patients with liver diseases generally express positive attitudes toward the benefits of supervised exercise, they also acknowledge a lack of confidence in initiating it independently.

Based on this evidence, an integrated exercise program is proposed, consisting of two phases: an initial supervised phase lasting eight weeks and a subsequent remote phase, combined with nutritional counseling and psychological support. It is hypothesized that this program will improve fatigue and consequently enhance quality of life, as well as alleviate associated cognitive symptoms (such as depression and sleep disturbances).

To better understand the changes occurring in the organs involved in fatigue, the investigators aim to analyze immune responses and bile acids to determine their potential association with fatigue, as has been observed in other autoimmune diseases. Additionally, potential alterations at both the brain and muscle levels will be explored.

At the neurological level, functional connectivity alterations in brain regions involved in fatigue will be studied using functional magnetic resonance imaging (fMRI). At the muscular level, changes in muscle metabolism will be analyzed by studying gene expression in muscle fibers. Muscle samples will be obtained using a minimally invasive technique called muscle microbiopsy, which involves a fine-needle puncture of a muscle and is not associated with complications. These studies will be conducted before and after the exercise program, aiming to observe the positive changes expected at all levels.

These studies will be conducted before and after the training program.

03

Conditions studied

  • Primary Biliary Cholangitis (PBC)

Keywords

  • FATIGUE
  • PREHABILITATION
  • PHYSICAL ACTIVITY
  • MINDFULNESS MEDITATION
  • NUTRITION
  • QUALITY OF LIFE
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • PBC diagnosis according to EASL guidelines
  • Moderate - severe fatigue defined by ≥ 29 points in PBC-40 questionnaire

Exclusion criteria

Exclusion Criteria:

  • Age > 80 years
  • Severe pruritus
  • Decompensated cirrhosis
  • Other causes of liver disease than PBC
  • Liver transplant (LT) o placement on a waiting-list for LT
  • Uncontrolled thyroid disesase
  • Anemia with \<11g/dl
  • Uncontrolled cardiovascular risk factors
  • > 35,
  • Acute myocardial infarct or unstable angina the past 6 months
  • Muscle disease or systemic disease with potential muscle involvement
  • Dysautonomy
  • Untreated osteoporosis
  • Untreated celiac disease
  • Alcohol consumption > 14 standard drinks (SD) in women and >21 (SD) in men per week
  • Chronic kidney disease ≥ 4 KDIGO stage
  • in the past two years (except for non melanoma skin cancer and in situ cervical carcinoma)
  • Not capable of performing or following the prehabilitation program
  • Involvement in a clinical trial the previous 2 months
  • Refusal of

For the study of the pathophysiology of fatigue, additional exclusion criteria will be established: Severe depression or neuropsychiatric disease, 2) Treatment with centrally acting drugs, 3) Muscular or systemic disease with potential muscle involvement, 4) treatment, 5) Sleep disorder, 6) Obesity (BMI >30).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Multimodal prehabilitation

    8 weeks program of tailored physical exercise program with nutritional and psychological counselling to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile.

    Other: Multimodal prehabilitation

  • Other
    Standard of care

    Standard Counselling: Patients in the control group will follow standard of care of the hospital and will be given general recommendations on physical activity, nutrition and stress/anxiety management.

    Other: standard of care

Interventions

  • OtherMultimodal prehabilitation

    The multimodal prehabilitation program will consist of: 1. twice-weekly supervised exercise training at the hospital gym for approximately 8 weeks (induction phase), followed by 16 weeks of telematic, supervised, home-based exercise (maintenance phase); 2. nutritional consultation, including diet optimization and supplementation if needed; 3. individual or group-based psychological support.

  • Otherstandard of care

    Participants in the control group will follow the standard of care provided by the hospital and will receive general recommendations on physical activity, nutrition, and stress/anxiety management.

06

What researchers measure

Primary outcomes

  1. Change in Fatigue Severity Assessed by PBC-40

    To evaluate the effect of a non-pharmacological multimodal intervention program on fatigue severity and its impact in participants with primary biliary cholangitis (PBC). Fatigue will be assessed using the Primary Biliary Cholangitis-40 (PBC-40) fatigue domain, which consists of 11 items scored from 1 to 5. Scoring Range: 11 to 55; higher scores indicate greater fatigue.

    Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).

  2. Change in Fatigue Severity Assessed by Visual Analogue Scale

    To evaluate the effect of a non-pharmacological multimodal intervention program on fatigue severity and its impact in participants with primary biliary cholangitis (PBC). Fatigue will be assessed using the Visual Analogue Scale (VAS) for fatigue, which captures the participant's perception of fatigue severity. Scoring Range: 0 (no fatigue) to 10 (worst imaginable fatigue).

    Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).

  3. Change in Fatigue Impact Assessed by Fatigue Impact Scale (FIS)

    To evaluate the effect of a non-pharmacological multimodal intervention program on fatigue severity and its impact in participants with primary biliary cholangitis (PBC). Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS), which assesses the impact of fatigue on physical, cognitive, and psychosocial functioning. Scoring Range: 0 to 84; higher scores indicate greater fatigue-related impairment

    Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).

Secondary outcomes

  1. Change in Cognitive Symptoms Assessed by PBC-40

    To evaluate changes in cognitive symptoms using the Primary Biliary Cholangitis-40 (PBC-40) questionnaire. The cognitive domain ranges from 6 to 30 points. Higher scores indicate worse symptoms.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  2. Change in Extrahepatic Symptoms Assessed by PBC-40

    To evaluate changes in extrahepatic symptoms using the Primary Biliary Cholangitis-40 (PBC-40) questionnaire. The symptoms domain ranges from 7 to 35 points. Higher scores indicate worse symptoms.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  3. Change in Quality of Life Assessed by EQ-5D-5L Index Score

    To assess health-related quality of life using only the EQ-5D-5L index score derived from five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The index score ranges from -0.594 to 1, where higher scores indicate better health status.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  4. Change in Self-Perceived Health Status Assessed by EQ Visual Analogue Scale

    To evaluate self-perceived overall health using the EQ Visual Analogue Scale (EQ-VAS), part of the EQ-5D-5L instrument, reported separately. The EQ-VAS ranges from 0 to 100, where 0 = worst imaginable health and 100 = best imaginable health.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  5. Change in Disability Assessed by the WHO Disability Assessment Schedule (WHODAS 2.0)

    To measure disability and functional impairment. Scoring Range: 0 to 100; higher scores indicate greater disability.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  6. Change in Anxiety and Depression Assessed by the Hospital Anxiety and Depression Scale (HADS)

    To evaluate levels of anxiety and depression. Scoring Range: 0 to 21 for each subscale (anxiety and depression); higher scores indicate greater symptom severity.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  7. Change in Sleep Quality Assessed by the Epworth Sleepiness Scale (ESS)

    To assess daytime sleepiness as a proxy for sleep quality. Scoring Range: 0 to 24; higher scores indicate greater daytime sleepiness.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  8. Change in Work Productivity and Activity Impairment Assessed by the WPAI Questionnaire

    To measure absenteeism and work productivity impairment. Percentage scores for absenteeism, presenteeism, overall work impairment, and activity impairment; higher percentages indicate greater impairment.

    Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.

  9. Change in Systemic Inflammation Assessed by Pro-Inflammatory Cytokines

    To evaluate systemic inflammation and bile acid metabolism by analyzing a panel of pro-inflammatory cytokines (measured via ELISA), lysophosphatidic acid, autotaxin, and bile acids. Each biomarker will be quantified by the laboratory using standardized assays. Units of Measure: Concentrations reported in appropriate laboratory units (e.g., pg/mL, nmol/L) depending on the biomarker.

    Time frame: Baseline and end of induction phase (2 months) for participants with fatigue; single time point for control groups.

  10. Functional Connectivity Alterations in Brain Regions Assessed by fMRI.

    To examine changes in functional connectivity in gray matter regions, including the basal ganglia and insula, using functional magnetic resonance imaging (fMRI).

    Time frame: Baseline and end of induction phase (2 months) for participants with fatigue; single time point for control groups.

  11. Changes in Muscle Mitochondrial Metabolism Assessed by Gene Expression Analysis

    To analyze gene expression profiles related to mitochondrial metabolism in muscle fibers obtained via muscle microbiopsy. Units of measure: Relative gene expression (fold change compared to baseline or control).

    Time frame: Baseline and end of induction phase (2 months) for participants with fatigue; single time point for control groups.

  12. Change in Aerobic Capacity

    Aerobic capacity will be evaluated to measure changes in functional exercise tolerance using the 6-Minute Walk Test (6MWT), which measures distance walked in meters (0-700 m typical; higher distances = better capacity). Unit of Measure: Meters.

    Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).

  13. Change in Physical Activity Levels

    Physical activity levels will be assessed to determine changes in habitual activity, with scores ranging from 0 to 142, where higher scores indicate greater overall physical activity.

    Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).

  14. Change in Frailty Status

    Frailty will be evaluated using the Liver Frailty Index (LFI), a continuous scale derived from a combination of grip strength, chair-stand time, and balance testing. In adult liver disease populations, median LFI values range approximately from 2.7 in individuals without liver disease to 3.6 in those with cirrhosis. Established thresholds classify LFI scores of \< 3.2 as "robust", 3.2-4.4 as "prefrail", and \> 4.4 as "frail"

    Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).

  15. Feasibility and Satisfaction of a Multimodal Rehabilitation Program for the Treatment of Fatigue

    Participant experience will be assessed using satisfaction questionnaires. Adherence to the intervention and loss to follow-up will be evaluated by analyzing reasons for non-compliance or withdrawal.

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Diaz-Feijoo B, Agusti N, Sebio R, Siso M, Carreras-Dieguez N, Domingo S, Diaz-Cambronero O, Torne A, Martinez-Palli G, Arguis MJ. A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE). Int J Gynecol Cancer. 2022 Nov 7;32(11):1463-1468. doi: 10.1136/ijgc-2022-003652. PubMed 35793862 ↗
  • Gimeno-Santos E, Coca-Martinez M, Arguis MJ, Navarro R, Lopez-Hernandez A, Castel MA, Romano B, Lopez-Baamonde M, Sandoval E, Farrero M, Sanz M, Bofill A, Martinez-Palli G. Multimodal prehabilitation as a promising strategy for preventing physical deconditioning on the heart transplant waiting list. Eur J Prev Cardiol. 2020 Dec;27(19):2367-2370. doi: 10.1177/2047487319889709. Epub 2019 Nov 25. No abstract available. PubMed 31766879 ↗
  • Barberan-Garcia A, Ubre M, Pascual-Argente N, Risco R, Faner J, Balust J, Lacy AM, Puig-Junoy J, Roca J, Martinez-Palli G. Post-discharge impact and cost-consequence analysis of prehabilitation in high-risk patients undergoing major abdominal surgery: secondary results from a randomised controlled trial. Br J Anaesth. 2019 Oct;123(4):450-456. doi: 10.1016/j.bja.2019.05.032. Epub 2019 Jun 25. PubMed 31248644 ↗
  • Williams FR, Vallance A, Faulkner T, Towey J, Kyte D, Durman S, Johnson J, Holt A, Perera MT, Ferguson J, Armstrong MJ. Home-based exercise therapy in patients awaiting liver transplantation: protocol for an observational feasibility trial. BMJ Open. 2018 Jan 21;8(1):e019298. doi: 10.1136/bmjopen-2017-019298. PubMed 29358444 ↗
  • Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau M, Ma M, Abraldes JG, Paterson I, Haykowsky MJ, Tandon P. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1920-6.e2. doi: 10.1016/j.cgh.2014.04.016. Epub 2014 Apr 24. PubMed 24768811 ↗
  • Watt M, Hyde A, Johnson E, Wright GM, Vander Well S, Sadasivan C, Lee-Baggley D, Spence JC, Mason A, Ko HH, Tam E, Tandon P. An online mind-body program improves mental health and quality of life in primary biliary cholangitis: A randomized controlled trial. Hepatol Commun. 2023 Nov 6;7(11):e0316. doi: 10.1097/HC9.0000000000000316. eCollection 2023 Nov 1. PubMed 38346279 ↗
  • Freer A, Williams FR, Durman S, Hayden J, Armstrong MJ, Trivedi PJ. A home-based exercise programme attenuates fatigue in primary biliary cholangitis: Results from the EXCITED clinical trial. JHEP Rep. 2024 Sep 6;6(12):101210. doi: 10.1016/j.jhepr.2024.101210. eCollection 2024 Dec. PubMed 39640219 ↗
  • Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Tadde B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators' Group; ELATIVE Study Investigators' Group. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. PubMed 37962077 ↗
  • Jopson L, Newton JL, Palmer J, Floudas A, Isaacs J, Qian J, Wilkinson J, Trenell M, Blamire A, Howel D, Jones DE. RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMJ Open. 2015 Aug 20;5(8):e007985. doi: 10.1136/bmjopen-2015-007985. PubMed 26297361 ↗
  • Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, Lindor KD. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci. 2006 Nov;51(11):1985-91. doi: 10.1007/s10620-006-9397-5. Epub 2006 Oct 20. PubMed 17053955 ↗
  • Silveira MG, Gossard AA, Stahler AC, Jorgensen RA, Petz JL, Ali AH, Lindor KD. A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. Am J Ther. 2017 Mar/Apr;24(2):e167-e176. doi: 10.1097/MJT.0000000000000387. PubMed 27148676 ↗
  • Lee JY, Danford CJ, Trivedi HD, Tapper EB, Patwardhan VR, Bonder A. Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2019 Aug;64(8):2338-2350. doi: 10.1007/s10620-019-5457-5. Epub 2019 Jan 10. PubMed 30632051 ↗
  • Hollingsworth KG, Newton JL, Taylor R, McDonald C, Palmer JM, Blamire AM, Jones DE. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol. 2008 Sep;6(9):1041-8. doi: 10.1016/j.cgh.2008.04.013. Epub 2008 Aug 8. PubMed 18691944 ↗
  • Yeaman SJ, Kirby JA, Jones DE. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev. 2000 Apr;174:238-49. doi: 10.1034/j.1600-0528.2002.00021h.x. PubMed 10807520 ↗
  • Hollingsworth KG, Newton JL, Robinson L, Taylor R, Blamire AM, Jones DE. Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis. J Hepatol. 2010 Jul;53(1):155-61. doi: 10.1016/j.jhep.2010.02.022. Epub 2010 Mar 31. PubMed 20447719 ↗
  • Goldblatt J, James OF, Jones DE. Grip strength and subjective fatigue in patients with primary biliary cirrhosis. JAMA. 2001 May 2;285(17):2196-7. doi: 10.1001/jama.285.17.2196. No abstract available. PubMed 11325320 ↗
  • Mosher VAL, Swain MG, Pang JXQ, Kaplan GG, Sharkey KA, MacQueen GM, Goodyear BG. Primary Biliary Cholangitis Alters Functional Connections of the Brain's Deep Gray Matter. Clin Transl Gastroenterol. 2017 Jul 27;8(7):e107. doi: 10.1038/ctg.2017.34. PubMed 28749455 ↗
  • D'Mello C, Swain MG. Liver-brain interactions in inflammatory liver diseases: implications for fatigue and mood disorders. Brain Behav Immun. 2014 Jan;35:9-20. doi: 10.1016/j.bbi.2013.10.009. Epub 2013 Oct 16. PubMed 24140301 ↗
  • Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry. 2012 Oct;69(10):1044-53. doi: 10.1001/archgenpsychiatry.2011.2094. PubMed 23026954 ↗
  • Dantzer R, Heijnen CJ, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci. 2014 Jan;37(1):39-46. doi: 10.1016/j.tins.2013.10.003. Epub 2013 Nov 13. PubMed 24239063 ↗
  • Nelson T, Zhang LX, Guo H, Nacul L, Song X. Brainstem Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Scoping Review and Evaluation of Magnetic Resonance Imaging Findings. Front Neurol. 2021 Dec 17;12:769511. doi: 10.3389/fneur.2021.769511. eCollection 2021. PubMed 34975729 ↗
  • Zeng J, Fan J, Zhou H. Bile acid-mediated signaling in cholestatic liver diseases. Cell Biosci. 2023 Apr 29;13(1):77. doi: 10.1186/s13578-023-01035-1. PubMed 37120573 ↗
  • Ronca V, Davies SP, Oo YH, Lleo A. The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects. Hepatology. 2025 Oct 1;82(4):877-894. doi: 10.1097/HEP.0000000000001225. Epub 2025 Jan 3. PubMed 39774114 ↗
  • Borren NZ, van der Woude CJ, Ananthakrishnan AN. Fatigue in IBD: epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):247-259. doi: 10.1038/s41575-018-0091-9. PubMed 30531816 ↗
  • Jopson L, Jones DE. Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management. Dig Dis. 2015;33 Suppl 2:109-14. doi: 10.1159/000440757. Epub 2015 Dec 7. PubMed 26641884 ↗
  • Ismond KP, Aziz B, Wright GM, Mason AL. Self-reported experiences of patients living with primary biliary cholangitis (PBC): Are we treating the liver but not the patient? Can Liver J. 2019 Feb 25;2(1):45-47. doi: 10.3138/canlivj.2018-0017. eCollection 2019 Winter. No abstract available. PubMed 35991832 ↗
  • Lynch EN, Campani C, Innocenti T, Dragoni G, Biagini MR, Forte P, Galli A. Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives. World J Hepatol. 2022 Jun 27;14(6):1111-1119. doi: 10.4254/wjh.v14.i6.1111. PubMed 35978669 ↗
  • Bjornsson E, Kalaitzakis E, Neuhauser M, Enders F, Maetzel H, Chapman RW, Talwalkar J, Lindor K, Jorgensen R. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int. 2010 Feb;30(2):251-8. doi: 10.1111/j.1478-3231.2009.02160.x. Epub 2009 Nov 17. PubMed 19922590 ↗
  • Wunsch E, Stadnik A, Kruk B, Szczepankiewicz B, Kotarska K, Krawczyk M, Gornicka B, Wojcicki M, Milkiewicz P. Chronic Fatigue Persists in a Significant Proportion of Female Patients After Transplantation for Primary Sclerosing Cholangitis. Liver Transpl. 2021 Jul;27(7):1032-1040. doi: 10.1002/lt.26033. Epub 2021 Apr 21. PubMed 33641247 ↗
  • Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005 Nov;54(11):1622-9. doi: 10.1136/gut.2005.065862. Epub 2005 Jun 16. PubMed 15961522 ↗
  • Montali L, Gragnano A, Miglioretti M, Frigerio A, Vecchio L, Gerussi A, Cristoferi L, Ronca V, D'Amato D, O'Donnell SE, Mancuso C, Luca M, Yagi M, Reig A, Jopson L, Pilar S, Jones D, Pares A, Mells G, Tanaka A, Carbone M, Invernizzi P. Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. J Transl Autoimmun. 2021 Jan 6;4:100081. doi: 10.1016/j.jtauto.2021.100081. eCollection 2021. PubMed 33554101 ↗
  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18. PubMed 28427765 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Sep 8, 2025
StartActual
Feb 6, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07161245
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Feb 6, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Helena Hernández Évole, MD
Contact
HEHERNANDEZ@clinic.cat
+34 932 27 54 00 ext. 2344
Sergio Rodríguez Tajes, MD, PhD
Contact
SRODRIGUEZ@CLINIC.CAT
Sergio Rodríguez Tajes, MD, PhD
principal investigator · Hospital Clinic of Barcelona
Marta Ubré Lorenzo, MD, PhD
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion